weekly glp 1 agonist Another milestone in the evolution of GLP-1-based diabetes therapies Table 1 from Glucagon-Like Peptide-1
Description
You may still be a candidate for the Fitish Microdosing program, a lower dose option for patients who want a gentler, cosmetic approach

GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030

Understanding current research, milk transfer data, and alternative timing strategies helps inform your decision about weight management during breastfeeding

Current evidence on drug transfer into breast milk is limited for most compounds, making provider consultation essential before starting or continuing treatment during lactation

Marc Jean, DO, FACOG
